The α5-GABAAR inverse agonist MRK-016 upregulates hippocampal BDNF expression and prevents cognitive deficits in LPS-treated mice, despite elevations in hippocampal Aβ.

The α5-GABAAR inverse agonist MRK-016 upregulates hippocampal BDNF expression and prevents cognitive deficits in LPS-treated mice, despite elevations in hippocampal Aβ. Behav Brain Res. 2018 Jul 19;: Authors: Eimerbrink MJ, Pendry RJ, Hodges SL, Wiles JD, Peterman JL, White JD, Hayes HB, Chumley MJ, Boehm GW Abstract Alzheimer's disease is marked by the presence of amyloid-beta (Aβ) plaques, elevated central cytokine levels, dysregulation of BDNF-related gene expression, and cognitive decline. Previously, our laboratory has demonstrated that repeated administration of peripheral LPS is sufficient to significantly increase the presence of central Aβ in the hippocampus, and that this upregulation corresponds with deficits in learning and memory. We have also previously demonstrated that the inverse benzodiazepine agonist MRK-016 (MRK) can protect against memory acquisition and consolidation errors in mice. To extend these findings, the current study explored the protective effects of MRK in the context of LPS-induced hippocampal Aβ accumulation. Hippocampal Aβ was significantly elevated, relative to saline-treated animals, following seven days of peripheral LPS injections. Animals were then trained in a contextual fear conditioning paradigm and were immediately treated with MRK or saline once training was complete. Behavioral testing occurred the day after training. Results from this study demonstrate that repeated injections...
Source: Behavioural Brain Research - Category: Neurology Authors: Tags: Behav Brain Res Source Type: research

Related Links:

Caring for someone with Alzheimer's disease can be both challenging and rewarding. Learn about tips to make it easier, as well as when to seek professional help.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
However, no link seen between migraines and vascular dementia
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Neurology, Psychiatry, Geriatrics, Journal, Source Type: news
Researchers at private Arizona-based firm NeuroEM Therapeutics tested their transcranial electromagnetic treatment (TEMT) on a group of eight patients with mild or moderate Alzheimer's.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Analyst, 2019, Accepted Manuscript DOI: 10.1039/C9AN00751B, PaperArthur Viode, Stephane Epelbaum, Imen Benyounes, Marc Verny, Bruno Dubois, Christophe Junot, francois Fenaille, Foudil Lamari, Francois Becher Tau and α-synuclein are central in several neurodegenerative diseases, including Alzheimer Disease (AD), Dementia with Lewy bodies (DLB) and Parkinson disease (PD). New analytical methods for precise quantification of cerebrospinal... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
Conditions:   Blood Brain Barrier;   Alzheimer Disease;   Cognitive Dysfunction;   Dementia Intervention:   Diagnostic Test: Contrast agent enhanced MRI using Gadovist Sponsors:   Charite University, Berlin, Germany;   Prof. Dr. med. Jochen Fiebach (Senior Physician) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Alzheimer Disease Interventions:   Dietary Supplement: Wismemo;   Dietary Supplement: Placebo Sponsors:   GenMont Biotech Incorporation;   Chang Gung Memorial Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
WEDNESDAY, Sept. 18, 2019 -- Migraines are a significant risk factor for Alzheimer disease (AD) and all-cause dementia, according to a study published online Sept. 4 in the International Journal of Geriatric Psychiatry. Rebecca E. Morton, from...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Source: Neuropsychiatric Disease and Treatment - Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
This Viewpoint describes setbacks in trials of disease-modifying therapies for Alzheimer disease and describes options for future research and clinical care.
Source: JAMA Psychiatry - Category: Psychiatry Source Type: research
ConclusionsWe examined the usefulness of voxel-based statistical analysis for amyloid PET. This method provides objectiveZ-score maps andZ-sum values, which were observed to be helpful as an adjunct to visual interpretation especially for cases with mild or limited A β accumulation. This approach could improve the Aβ detection sensitivity, reduce inter-reader variability, and allow for detailed monitoring of Aβ deposition.Trial registrationThe number of the J-ADNI study isUMIN000001374
Source: EJNMMI Research - Category: Radiology Source Type: research
More News: Alzheimer's | Brain | Genetics | Laboratory Medicine | Learning | Neurology | Study | Training | Universities & Medical Training